Prime Therapeutics announced its 2023 recommendations for formularies that include AbbVie’s Humira® (adalimumab). The pharmacy benefit manager will recommend coverage of the following adalimumab biosimilars to commercial clients:
- Amgen’s Amjevita® (low concentration) and Boehringer Ingelheim’s Cyltezo® (interchangeable low concentration); or
- Amgen’s Amjevita® (low concentration) and Samsung Bioepis/Organon’s Hadlima® (high and low concentration).
Prime is also recommending coverage of Cyltezo® for Medicare Part D formularies. On 10 July 2023, Cigna Health announced its preferred adalimumab biosimilars.